Introduction: Lyme borreliosis has been associated with lymphoma, particularly cutaneous lymphomas. The literature is conflicted regarding the effect of antibiotic therapy in cutaneous marginal zone lymphomas (MZLs) in individuals with Lyme borreliosis. We present a patient diagnosed with Lyme neuroborreliosis (LNB) and disseminated MZL.
Case Presentation: A 67-year-old man was seen due to 6 weeks of neuropathic pain with nightly worsening, headache, and 5 kg weight loss. Two weeks prior to symptom debut, he had a tick bite in the left groin, no subsequent rash. A lumbar puncture revealed mononuclear pleocytosis and elevated CSF protein. The patient was admitted and started on ceftriaxone. The intrathecal test showed intrathecally produced antibodies, and treatment was changed to doxycycline with a total treatment duration of 21 days. A PET/CT revealed enlarged lymph nodes with increased FDG uptake. On pathological examination, the CSF showed 62% clonal B cells - compatible with low-grade B-cell lymphoma. Examination of bone marrow and an inguinal lymph node confirmed disseminated MZL. A control lumbar puncture 8 weeks later showed declining pleocytosis and clonal B cells. At last follow-up 20 months later, he was still asymptomatic and had not required antineoplastic treatment.
Conclusion: To our knowledge, this is the first published case of LNB with non-cutaneous B-cell lymphoma treated and remitting on antibiotics alone. Antibiotic treatment for -positive lymphomas has yet to be investigated with high-evidence study designs, so clinicians are encouraged to publish both positive and negative findings relevant to this. We believe this case brings new perspectives to future diagnosis and treatment of lymphomas in patients with verified Lyme borreliosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11810129 | PMC |
| http://dx.doi.org/10.1159/000543348 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extravasation of Borrelia burgdorferi Across the Blood-Brain Barrier is an Extremely Rare Event.
Adv Sci (Weinh)
March 2025
Institute for Nanobiotechnology, Johns Hopkins University, 3400 N Charles St, Baltimore, MD, 21218, USA.
Lyme disease, the most widespread tick-borne disease in North America, is caused by the bacterium Borrelia burgdorferi (Bb). Approximately 10-15% of infections result in neuroborreliosis, common symptoms of which include headaches, facial palsy, and long-term cognitive impairment. Previous studies of Bb dissemination focus on assessing Bb transmigration at static time points rather than analyzing the complex dynamic process of extravasation.
View Article and Find Full Text PDFProposed research classification criteria for Lyme disease in infection associated chronic illness studies.
Front Med (Lausanne)
February 2025
Lyme Disease Research Center, Baltimore, MD, United States.
Background: Research on patients with persistent symptoms despite prior treatment for Lyme disease can be challenging to interpret given the diversity of criteria selected to characterize Lyme disease and to define the syndrome of those with persistent symptoms. Because most research studies only include patients with well-documented prior Lyme disease, the generalizability of the study results is limited, excluding the larger group of patients often seen in community practice who do not meet these stringent enrollment criteria. Researchers at the Lyme and other Tick-borne Diseases Clinical Trials Network (LTD-CTN) recognized early on that a research classification system was needed to facilitate the design of studies that are more inclusive.
View Article and Find Full Text PDFLyme Carditis: A Reversible Culprit in Non-Ischemic Cardiomyopathy.
Cureus
February 2025
Internal Medicine, University of Florida College of Medicine, Gainesville, USA.
Lyme disease (LD), caused by , is a tick-borne illness that can lead to Lyme carditis, which most commonly presents as a high-degree atrioventricular (AV) block. While conduction abnormalities are well-documented, LD has also been implicated in non-ischemic cardiomyopathy, though this manifestation remains rare and under-recognized. We present the case of a 57-year-old female with newly diagnosed heart failure with reduced ejection fraction (HFrEF) and first-degree AV block, who initially presented with nausea, dizziness, fatigue, and gastrointestinal symptoms.
View Article and Find Full Text PDFTick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021.
Sci Rep
March 2025
Microbiologie, ADMED Analyses et Diagnostics Médicaux, La Chaux-de-Fonds, Switzerland.
Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort.
View Article and Find Full Text PDFUHPLC-MS/MS-based untargeted metabolite profiling of Lyme neuroborreliosis.
Sci Rep
March 2025
Department of Chemistry, University of Turku, Turku, Finland.
The diagnosis of Lyme neuroborreliosis (LNB) requires the demonstration of intrathecal synthesis of Borrelia antibodies in a patient's cerebrospinal fluid (CSF), which involves the invasive procedure of a lumbar puncture. This study serves as a feasibility study aimed at exploring the potential of using serum samples, which are easily obtainable routine clinical samples, for LNB diagnostics via advanced metabolomics techniques. Serum samples were collected from confirmed LNB patients before and after treatment, with post-treatment samples serving as controls.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!